Associated Papers
Oral Melanocytic Neoplasms: A Narrative Review.
Maldonado-Mendoza J
Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2025
Epigenetic MLH1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques.
Deycmar S et al.
Journal of Translational Medicine, 2024
The Clinicopathological Correlation of KRAS Mutation and PTEN Expression Status in Primary and Metastatic Colorectal Carcinoma.
Hassan RT et al.
Cureus, 2024
Genomic profiling informs diagnoses and treatment in vascular anomalies.
Li D et al.
Nature Medicine, 2023
Sclerosing Polycystic Adenoma of Salivary Glands: A Novel Neoplasm Characterized by PI3K-AKT Pathway Alterations-New Insights Into a Challenging Entity.
Skálová A et al.
The American Journal of Surgical Pathology, 2022
Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacological Research, 2021
Proteogenomic characterization of pancreatic ductal adenocarcinoma.
Cao L et al.
Cell, 2021
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.
Malapelle U et al.
European Journal of Cancer (oxford, England : 1990), 2021
Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.
Osumi H et al.
Cancer Medicine, 2019
Metastases risk in thin cutaneous melanoma: prognostic value of clinical-pathologic characteristics and mutation profile.
Richetta AG et al.
Oncotarget, 2018
Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas.
Shimura T et al.
Oncotarget, 2018
Oncogene mutational analysis in Chinese gastrointestinal stromal tumor patients.
Chen Q et al.
Oncotargets and Therapy, 2018
Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.
Jones M et al.
Gastrointestinal Endoscopy, 2016
Mosaic Neurocutaneous Disorders and Their Causes.
Ruggieri M et al.
Seminars in Pediatric Neurology, 2015
RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM et al.
Endocrine-related Cancer, 2015
Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
Zou M et al.
Thyroid : Official Journal of the American Thyroid Association, 2014
Novel somatic and germline mutations in intracranial germ cell tumours.
Wang L et al.
Nature, 2014
Reporting tumor molecular heterogeneity in histopathological diagnosis.
Mafficini A et al.
Plos One, 2014
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
Ciampi R et al.
Thyroid : Official Journal of the American Thyroid Association, 2013
Keratinocytic epidermal nevi are associated with mosaic RAS mutations.
Hafner C et al.
Journal of Medical Genetics, 2012
KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
Tie J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L et al.
Cancer, 2010
A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.
Fumagalli D et al.
Bmc Cancer, 2010
Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma.
Jovanovic B et al.
The Journal of Investigative Dermatology, 2008
A comprehensive procedural approach to genotyping KRAS and BRAF from paraffin embedded tissues for diagnostic purposes.
Palmirotta R et al.
In Vivo (athens, Greece), 0